

Resource Summary Report

Generated by [PRECISE-TBI](#) on Sep 19, 2026

GenomeJack

RRID:SCR_012026

Type: Tool

Proper Citation

GenomeJack (RRID:SCR_012026)

Resource Information

URL: <http://genomejack.net/>

Proper Citation: GenomeJack (RRID:SCR_012026)

Description: A genome browser specialized in next-generation sequencing data.

Abbreviations: GenomeJack

Resource Type: software resource

Keywords: next-generation sequencing, genome, browser, analysis

Availability: Free, Public

Resource Name: GenomeJack

Resource ID: SCR_012026

Alternate IDs: OMICS_02143

Record Creation Time: 20220129T080308+0000

Record Last Update: 20260912T195743+0000

Ratings and Alerts

No rating or validation information has been found for GenomeJack.

No alerts have been found for GenomeJack.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 35 mentions in open access literature.

Listed below are recent publications. The full list is available at [PRECISE-TBI](#) .

Zennami K, et al. (2026) Genomic Profiling in Localized Prostate Cancer: Associations With Biochemical Recurrence and Response to Salvage Radiotherapy. *Cancer science*, 117(5), 1469.

Yanagi H, et al. (2026) Establishment of a Large-Scale PDX Library of Head and Neck Cancers for Functional Precision Oncology. *Cancer medicine*, 15(2), e71521.

Hirano T, et al. (2026) Prognostic Biomarker of Fertility-Preserving Hormonal Therapy Based on Multigene Panel Testing for Endometrial Cancer. *Cancer science*, 117(1), 236.

Chikaishi Y, et al. (2025) Mutation Analysis of TMB-High Colorectal Cancer: Insights Into Molecular Pathways and Clinical Implications. *Cancer science*, 116(4), 1082.

Imaeda K, et al. (2025) LCN2-mediated ferroptosis resistance in tissue homeostasis and early-stage tumorigenesis of the fallopian tube epithelium. *iScience*, 28(6), 112654.

Arai M, et al. (2025) Prognostic impact and landscape of cellular CXCR5 chemokine receptor expression in clear-cell renal cell carcinoma. *Cancer immunology, immunotherapy : CII*, 74(5), 166.

Nagase Y, et al. (2025) CXCL9 and CXCL13 shape endometrial cancer immune-activated microenvironment via tertiary lymphoid structure formation. *Cancer science*, 116(5), 1193.

Takaoka H, et al. (2025) Clinical Application of In-House Comprehensive Genomic Profiling for Thoracic Cancer: Insights From a Japanese Hospital. *Cancer science*, 116(10), 2819.

Takano N, et al. (2024) Genetic and histological analysis intraplacental choriocarcinoma: a case report. *Medical molecular morphology*, 57(2), 147.

Saito A, et al. (2024) Clinical utility of the Oncomine Dx Target Test multi-CDx system and the possibility of utilizing those original sequence data. *Cancer medicine*, 13(4), e7077.

Kaneko Y, et al. (2024) Volumetric imaging of the tumor microvasculature reflects outcomes and genomic states of clear cell renal cell carcinoma. *The journal of pathology. Clinical research*, 10(4), e12388.

Takamatsu R, et al. (2023) Clinical predominance of whole-exome sequencing to evaluate microsatellite instability status. *Cancer science*, 114(7), 2848.

Kobayashi H, et al. (2023) Genomic analysis of aggressive ductal adenocarcinoma of the prostate. *Cancer medicine*, 12(7), 8445.

Nukaya T, et al. (2023) Estimating copy number to determine BRCA2 deletion status and to expect prognosis in localized prostate cancer. *Cancer medicine*, 12(7), 8154.

Yanagita E, et al. (2023) The DNA integrity number and concentration are useful parameters for successful comprehensive genomic profiling test for cancer using formalin-fixed paraffin embedded tissue. *Pathology international*, 73(5), 198.

Hsu CY, et al. (2023) Eribulin inhibits growth of cutaneous squamous cell carcinoma cell lines and a novel patient-derived xenograft. *Scientific reports*, 13(1), 8650.

Masuda T, et al. (2022) Unique characteristics of tertiary lymphoid structures in kidney clear cell carcinoma: prognostic outcome and comparison with bladder cancer. *Journal for immunotherapy of cancer*, 10(3).

Kurose S, et al. (2021) Whole-Exome Sequencing of Rare Site Endometriosis-Associated Cancer. *Diseases (Basel, Switzerland)*, 9(1).

Hossain MM, et al. (2021) Establishment of a Novel In Vitro Model of Endometriosis with Oncogenic KRAS and PIK3CA Mutations for Understanding the Underlying Biology and Molecular Pathogenesis. *Cancers*, 13(13).

Shimozaki K, et al. (2021) Concordance analysis of microsatellite instability status between polymerase chain reaction based testing and next generation sequencing for solid tumors. *Scientific reports*, 11(1), 20003.